SK Discovery

SK Discovery is a pure holding company formed in 2017 through a spin-off from the former SK Chemicals that separated the investment and operating businesses; it has no operations of its own and generates income by managing subsidiary stakes and providing funding and technical support.

Its core subsidiaries are SK Chemicals, which runs eco-friendly materials and pharmaceutical businesses, and SK Gas, which distributes LPG and LNG and operates power generation; under SK Chemicals sits SK Bioscience, which handles vaccine and biopharmaceutical contract development and manufacturing (CDMO).

SK Chemicals has reorganized its business around two pillars: Green Chemicals (resins and fine chemicals) and Life Science (vaccines and pharmaceuticals).

SK Gas operates LPG import terminals in Ulsan and Pyeongtaek along with a nationwide sales and distribution network, and through affiliate SK Advanced it has built vertical integration from propane to propylene to polypropylene in gas chemicals.

The group has continued rebalancing its portfolio away from non-core or lower-return assets, including an approved change of controlling shareholder at former renewable-energy subsidiary SK Ecoplant's affiliate.

In September 2025 the company signed a contract to sell its entire stake in joint venture SK D&D to a Hahn & Company-affiliated entity, with the transaction closing in the first half of 2026.

On a standalone basis, dividends from SK Gas account for more than 80% of total dividend income, reflecting heavy reliance on that single subsidiary. Beyond that, the group's biohealth footprint extends further through SK Plasma, which produces plasma-derived blood products.

Annual revenue rose for four consecutive years, from KRW 8.72tn in 2022 to KRW 10.16tn in 2025, but owners' net profit swung sharply, falling from KRW 427.4bn in 2022 to KRW 191.0bn in 2023 and KRW 25.2bn in 2024 before recovering to KRW 129.3bn in 2025.

The operating margin followed a similar path, dropping from 4.2% in 2022 to 1.9% in 2024 before rebounding to 3.6% in 2025. Quarterly figures show even sharper swings.

Operating profit was a solid KRW 168.1bn in Q3 2025, but the company posted an operating loss of KRW 5.47bn in Q4 2025 even as owners' net profit came in at KRW 53.2bn, suggesting non-operating items such as equity-method gains or derivative valuations had a material effect on the bottom line.

Q1 2026 was the strongest of the trailing four quarters, with revenue of KRW 3.29tn, operating profit of KRW 189.8bn, and owners' net profit of KRW 168.3bn.

Q2 2026, however, reversed into an operating loss of KRW 30.4bn and a net loss attributable to owners of KRW 46.8bn despite revenue of KRW 3.06tn, marking a wide swing from the prior quarter.

This volatility appears to reflect a combination of the seasonal LPG and petrochemical cycle, swings at subsidiaries such as SK Bioscience, and non-operating items tied to derivatives and equity-method affiliates.

Over the trailing four quarters (Q3 2025 through Q2 2026), cumulative owners' net profit totaled KRW 187.6bn, an improvement when annualized relative to full-year 2025.

The domestic LPG industry that SK Gas operates in is mature but is seen as maintaining a stable earnings structure, with an average adjusted operating margin of around 7% over the past five years including foreign exchange and derivative gains.

In 2025, however, weaker petrochemical market conditions reduced domestic sales volume, an effect largely offset by overseas trading gains. The PDH (propylene production) business run by affiliate SK Advanced has continued to underperform amid global oversupply, weighing on SK Gas's equity-method results.

Credit rating agencies view the strong creditworthiness of core affiliates SK Gas (AA-) and SK Chemicals (A+) as the foundation for SK Discovery's own credit standing.

In vaccines and biopharma, SK Bioscience is in a transition period after the end of the COVID-19 windfall, expanding its business model from self-developed vaccines toward global contract manufacturing through German CDMO subsidiary IDT Biologika, with the industry watching IDT's profit generation and clinical results for its pneumococcal vaccine candidate as re-rating catalysts.

As a pure holding company, SK Discovery's earnings are inherently tied to the business cycles of its affiliates—LPG market conditions and vaccine development outcomes—placing it in a similar competitive position to other domestic holding companies whose core revenue source is subsidiary dividends and equity value.

SK Bioscience is conducting a global Phase 3 trial in the United States and Europe for GBP410, a 21-valent pneumococcal conjugate vaccine candidate co-developed with Sanofi, and has stated it is targeting interim results in the second half of 2027.

German subsidiary IDT Biologika has posted operating profit for four consecutive quarters since Q3 2025, and the company plans to expand high-value-added CDMO contracts and secure new customers across North America, Europe, and Asia in the second half.

Expansion of commercial production facilities at the Andong L HOUSE has been completed, providing manufacturing capacity to support future global supply growth, and the company secured roughly KRW 300bn in low-interest, long-term financing after being selected for a national growth fund program, to be used for R&D and facility upgrades.

Its in-house influenza vaccine SkyCellFlu has expanded its footprint in overseas public procurement by signing new supply agreements with the Pan American Health Organization (PAHO) and UNICEF, while securing the maximum allocation under Korea's national immunization program domestically.

SK Gas continues to benefit from the commercial operation of the Ulsan GPS LPG/LNG combined-cycle power plant, and the company plans to keep diversifying through LNG direct-import and terminal businesses.

At the group level, following the completed divestiture of SK D&D, additional portfolio rebalancing measures—including a potential sale of the SK Ecoplant Renewables stake and minority stakes in Ulsan GPS and SK Multi Utility—are reportedly under review.